Oral icotrokinra: high clearance rates against placebo at 16 weeks

Design

Systematic review and meta-analysis of 5 randomised placebo-controlled trials

Population

Adolescents and adults with moderate-to-severe plaque psoriasis

Primary outcome

IGA 0 or 1 at week 16

Effect

RR 7.27 (5.80 to 9.11), I² 0%; PASI 90 RR 13.8 (7.21 to 26.5)

This meta-analysis pooled five randomised placebo-controlled trials, one phase 2 and four phase 3, of icotrokinra in adolescents and adults with moderate-to-severe plaque psoriasis. Icotrokinra is an oral peptide that blocks the IL-23 receptor, the same pathway targeted by injectable biologics such as guselkumab and risankizumab.

At week 16, icotrokinra made an Investigator's Global Assessment of 0 or 1 about seven times more likely than placebo (RR 7.27, 95% CI 5.80 to 9.11, I² 0%). PASI 90 was also far more frequent (RR 13.8, 7.21 to 26.5). Treatment-emergent and serious adverse events were similar to placebo over the 16 weeks, with no new safety signal.

A tablet with biologic-range efficacy would matter for patients who refuse or cannot manage injections. But all the comparisons here are against placebo, the follow-up is short, and the record does not state the drug's approval status in any country, including India. It is a drug to watch rather than one to plan around yet.

• Note that the evidence compares icotrokinra with placebo only, not with injectable IL-23 or IL-17 biologics.
• Expect questions from patients who prefer a tablet to injections; the efficacy data are encouraging.
• Check local regulatory status and availability before discussing it as an option.
• Keep established systemic therapy choices unchanged until longer-term and comparative data are published.
• Remember that 16-week safety data cannot reveal rare or delayed adverse effects.

Why it matters

An oral drug acting on the IL-23 pathway could change who reaches biologic-level control.

Don't overread it

Placebo-controlled 16-week trials do not show it is as good as, or safer than, injectable biologics.

The statistics, in plain English

A risk ratio of 7.27 means clear or almost clear skin was about seven times as common as with placebo; the narrow interval and I² of 0% show the trials agreed. Large ratios against placebo are expected for any effective psoriasis drug, so they say nothing about how it compares with existing biologics.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.